In addition to its existing indication for the treatment of de-novo lesions in native coronary arteries, the Taxus liberte stent system is now indicated in Europe for the treatment of acute myocardial infarction, total occlusions and in-stent restenosis. These three new indications account for more than 20% of all coronary interventions.
The new labeling reflects a review of clinical data by the regulatory agency. Boston's stent is now the only drug-eluting stent system with these new indications for use in Europe.
“The European approval for new indications recognizes the strong long-term performance of the Taxus stent system across complex patients and lesions,” said Jeff Goodman, president of Boston Scientific. “It allows physicians to treat difficult cases of coronary artery disease with the most advanced technology.”